Document is current
Any future updates will be listed below
-
Authors
Mourmans, Sanne G. J.
Achten, Anouk
Hermans, Raquel
Scheepers, Marijne J. E.
D’Alessandro, Elisa
Swennen, Geertje
Woudstra, Janneke
Appelman, Yolande
Goor, Harry van
Schalkwijk, Casper
Knackstedt, Christian
Weerts, Jerremy
Eringa, Etto C.
van Empel, Vanessa P. M.
-
Funding
Funding for this research was provided by:
Vaillantfonds
Dutch Cardiovascular Alliance Consortium IMPRESS (2020B004, 2020B004)
Dutch Heart Foundation CVON RECONNEXT consortium (2020B008)
ZonMw (09120232310119)
Cardiovascular Research Institute Maastricht
Health Foundation Limburg
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 10 March 2025
First Online: 25 April 2025
Declarations
:
: This study complies with the declaration of Helsinki and was approved by the Medical Ethics Committee University Hospital Maastricht/ Maastricht University as a low-intervention clinical trial according to the Clinical Trial Regulation (EU CT 2022-501682-45). All patients provided written informed consent before enrolment.
: Not applicable.
: V.P.M.v.E received sponsoring/grants from Roche, Vifor Pharma, Boehringer Ingelheim, Astra Zeneca and Pfizer (paid to institute), and received consultancy fees from Novartis, Janssen, Boehringer Ingelheim, Novonordisk (paid to institute).Pfizer and Astra Zeneca provided an unrestricted research grant to Maastricht University Medical Centre.C.K. received consulting fees from Pfizer, Novartis, BMS, and Alnylam (paid to institute).J.W. received grants from Corvia Medical, CSL Vifor, and Boehringer Ingelheim and is a member of the scientific committee on Atrial Disorders of the Heart Failure Association of the European society of cardiology.
